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Abstract 
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder, which currently 
affects nearly 5.5 million people in the United States alone. Clinical features often 
exhibited in AD include memory loss, unusual behavior, personality changes, and 
impaired cognitive function. The primary molecular hallmarks of AD include deposits of 
senile plaques and neurofibrillary tangles in brain tissue. A myriad of risk factors are 
associated with the disease, but this review will focus on Apolipoprotein E 
polymorphisms and certain environmental factors. Understanding the role of 
Apolipoprotein E in AD pathology may aid in the development of certain drug therapies 
and possible cures for AD. Moreover, epigenetic mechanisms such as deoxyribonucleic 
acid (DNA) methylation are equally important in understanding AD pathology. 
Environmental factors may have the potential to induce the epigenetic mechanisms 
associated with AD. As a result of these new findings, the focus of some AD research has 
recently shifted to a preventive approach in understanding AD pathology. The 
relationship between Apolipoprotein E polymorphisms and environmental factors in AD 
pathology will address the importance of preventive measures that can be taken in regard 
to AD. 
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Contributions of Apolipoprotein E and Environmental Factors in Alzheimer’s Disease 
History and Background of Alzheimer’s Disease 
 Alzheimer’s disease (AD), the most common form of dementia, is a progressive 
neurodegenerative disorder characterized by memory loss, unusual behavior, personality 
changes, and impaired cognitive function. The hallmarks of the disease include loss and 
damage of neurons, intracellular protein deposits known as neurofibrillary tangles, and 
extracellular protein deposits referred to as amyloid-beta plaques or senile plaques 
(Parihar & Hemnani, 2004). Despite advanced imaging techniques such as positron 
emission tomography (PET), functional magnetic resonance imaging (fMRI), computer-
assisted tomography, hydrogen magnetic resonance spectroscopy (1H MRS), and 
magnetic resonance spectroscopy (MRS), a definitive diagnosis of AD can only be made 
post-mortem by way of a brain autopsy, which can confirm the relationship between 
clinical features and the presence of senile plaques and neurofibrillary tangles in brain 
tissue (Brody, 2011; Parihar & Hemnani, 2004).  
 Alzheimer’s disease was first described by Alois Alzheimer, a German 
neuropsychiatrist and neuropathologist. Alzheimer firmly believed that clinical work and 
laboratory research, although separate disciplines, were essential to the development of 
both. Taking this approach, Alzheimer showed keen interest in his patients and their 
behavior as well as the examination of their brains after their death. One of Alzheimer’s 
patients was Auguste Deter, a 50-year-old woman exhibiting significant cognitive decline 
in the form of delirium, hallucinations, memory problems, apathy, and ultimately 
muteness and unresponsiveness.  Although Alzheimer was not the first to report on 
amyloid plaques, he was the first to notice neurofibrillary tangles. Alzheimer first noticed 
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the characteristic neurofibrillary tangles in Deter’s brain after her death. Subsequent 
findings similar to Deter’s case soon became more common, and Alzheimer’s coworker, 
Emil Kraepelin, considered these findings to be consistent with his own ideas on brain 
psychiatry. Kraepelin soon dubbed this new illness a disease and referenced it as 
Alzheimer’s disease in his next edition of Textbook of Psychiatry (Verhey, 2009). 
 The dawn of a newly recognized disease always feeds a heightened interest and 
desire by both the medical and scientific communities to meticulously research and solve 
the new problem. In the past 100 years, great measures have been taken to understand 
and combat AD. The past 30 years have met significant success in AD research as many 
advancements have been made in the disciplines of genetics, epigenetics, molecular 
biology, and biochemistry (Alzheimer's Association, 2012). Despite the advancements 
made in AD research, many people still continue to suffer from the disease. 
 Since the case of Auguste Deter, millions of people have been diagnosed with 
AD. Worldwide, the disease has affected over 25 million people (Dalvi, 2012). In the 
United States alone, nearly 5.4 million people had AD in 2012, with 5.2 million of those 
people being 65 and older. These numbers are expected to rise significantly in the coming 
years as the baby boomer generation ages and as technological advances allow for longer 
life expectancy. It has been projected that by the year 2050, 11 million to 16 million 
people in the United States will have AD, ignoring the possible development of cures for 
the disease by that time. These predictions are illustrated in Figure 1. With cases of AD 
on the rise, the economic impact is daunting. The cost of care is expected to rise 
significantly.  
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In 2012, the total cost for health care, long-term care, and hospice for patients with AD 
amounted to $200 billion and is expected to reach $1.1 trillion by 2050 (Alzheimer's 
Association, 2012).  
 AD presents in two forms, early-onset and late-onset. Individuals with early-onset 
AD show symptoms before 65 years of age, while people with late-onset AD show 
symptoms at 65 years or older. Late-onset AD constitutes the majority of AD cases 
(Koedam et al., 2010). Symptoms progress within three domains. Cognitive symptoms 
present first followed by behavioral symptoms and finally ending in functional symptoms 
(Dalvi, 2012). Although symptoms vary from person to person, memory loss is typically 
the first symptom that people develop. Because neuron function is impaired in regions of 
the brain used for forming new memories, short-term memory function is severely 
affected. Memory loss then leads to other challenges such as having difficulty in 
completing familiar tasks in daily life, being confused with time and place, misplacing 
items and being unable to retrace one’s steps to find those items, and having difficulty 
understanding visual images and spatial relationships. Symptoms progressively become 
worse as behavioral changes become more apparent. People may show drastic changes in 
mood and personality and may become socially withdrawn. In the final stages, people 
with AD lose functional abilities and do not recognize loved ones. Assistance must be 
provided in bathing, dressing, eating and using the bathroom. Ultimately, the individual 
becomes bed-ridden and becomes extremely susceptible to infection, notably pneumonia. 
At this point, AD is fatal (Alzheimer's Association, 2012). 
 A variety of risk factors are associated with AD, age being the leading risk factor. 
By the time a person reaches 65 years of age, the chances of developing AD doubles 
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every 5 years thereafter. By age 90, an individual has a 35%-40% chance of having the 
condition. Genes also serve as a risk factor for AD. The most well known genetic risk 
factors are mutations in genes such as amyloid precursor protein (APP), presenilin-1 
(PSEN-1), and presenilin-2 (PSEN-2) and the ε4 allele of apolipoprotein E (APOE) 
(Welsh-Bohmer, Plassman, & Hayden, 2010). Familial and twin studies have confirmed 
the large role that genetic factors play in AD. In addition to age and certain genes, 
environmental factors working through epigenetic mechanisms are also thought to 
contribute to AD risk (Dalvi, 2012). 
  Until more can be revealed about the causes of AD and the genetic and molecular 
influences involved in its pathology, AD will remain insatiable in its course of robbing 
societies not only economically but also relationally. The future, however, is not entirely 
grim. New findings continue to be made regarding the role of genetics in AD pathology. 
Moreover, how gene expression can be altered through various environmental exposures 
is a promising avenue to understanding the disease more fully. Genes do not have to seal 
a person’s fate. To see a glimpse of both the genetic and environmental factors involved 
in AD pathology, a protein directly involved in the process known as apolipoprotein E 
(ApoE) will be investigated in detail followed by an explanation of how environmental 
factors alongside ApoE may influence AD pathology. 
Biology of Apolipoprotein E (ApoE) 
 Knowing that genetics significantly contribute to the pathology of AD, scientists 
have intensely studied and searched out genes thought to be associated with AD. To date, 
researchers have identified over 660 genes that are suspected to be associated with AD.  
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One gene in particular, accounting for up to 50% of the known genetic contribution to 
AD, is known as APOE, the first gene discovered to have a correlation with late-onset 
AD. Consequently, APOE has been extensively researched (Welsh-Bohmer et al., 2010). 
APOE is responsible for encoding apolipoprotein E (ApoE), a protein involved in the 
transport of lipids throughout the body.  
Structure of Apolipoprotein E 
 To better understand the function of ApoE, its structure must first be understood. 
The APOE gene is found on the long arm of chromosome 19 at position 13.2 and consists 
of 1223 base pairs and is made of four exons. The protein product is a 34-kDa protein 
consisting of 299 amino acids, which are arranged into two structural domains, an N-
terminal domain and a C-terminal domain. A hinge region separates the two domains. 
Four amphipathic α-helices make up the N-terminus, and of particular interest is the 
fourth α-helix, whose characteristic kinks are responsible for constituting the low-density 
lipoprotein (LDL) receptor-binding region of ApoE. Many basic amino acids constitute 
this region of the protein and account for the evident kinks in the N-terminus. The 
binding ability of ApoE in the N-terminus is heavily influenced by the presence of many 
basic amino acids (Hsieh & Chou, 2011). The C-terminal domain, made up of amino 
acids ~225-299, contains the lipid binding region which is comprised of amino acids 
~244-272. The amino acid sequence is crucial to the binding ability of the protein. Figure 
2 illustrates the ApoE characteristics described above (Mahley, Weisgraber, & Huang, 
2009). 
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Function of Apolipoprotein E    
 Understanding the function of a protein is essential, but knowing where that 
protein is made and used in the body is equally important. Primarily, the liver and brain 
are responsible for synthesizing ApoE. Lesser amounts of ApoE are synthesized in the 
adrenal glands and the kidneys (Elshourbagy, Liao, Mahley, & Taylor, 1985). Originally, 
astrocytes, oligodendrocytes, and ependymal layer cells were the only known source of 
ApoE synthesis in the brain. However, according to recent studies, neurons may produce 
ApoE in small quantities when under pathophysiological stress (Xu et al., 2006). 
 Apolipoprotein E performs various functions, but its primary function is to 
catabolize and transport triglyceride-rich lipoprotein constituents thus allowing for proper 
transport and circulation of lipoproteins, fat-soluble vitamins, and cholesterol throughout 
the body but primarily in the brain (Singh, Singh, & Mastana, 2002). Cholesterol, for 
example, is essential for proper brain function, considering cholesterol is a component of 
cellular membranes and myelin sheaths within the brain. Ultimately, synaptic integrity 
and neuronal function depend heavily on cholesterol transport within the brain by way of 
the contributing activities of ApoE (Pfrieger, 2003). Astrocytes hold the primary 
responsibility of producing brain ApoE/lipoprotein particles. After astrocytes have 
produced ApoE/lipoprotein particles, cholesterol and other lipids are delivered to neurons 
to support neuronal synapses by way of interactions between ApoE receptors and ApoE 
(Bu, 2012). See Figure 3 for the role of ApoE in lipid transport within the brain.  
 To ensure that synapse formation is carried out successfully, the following steps 
must be met. First, astrocytes synthesize and secrete ApoE, which then combines with 
cholesterol and other lipids to form lipoprotein particles. The assembly of ApoE and 
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lipids to form lipoprotein particles is conducted by a plasma membrane transporter called 
ATP-binding cassette, sub-family A (ABCA1). After lipoprotein formation, one of two 
paths can be taken. The ApoE-lipoprotein particles will either bind to the neuronal ApoE 
receptors known as, low-density lipoprotein receptors (LDLRs) and low-density 
lipoprotein receptor-related protein 1 (LRP1), or will be transported to the cerebrospinal 
fluid (CSF). Moreover, instead of going directly to neuronal ApoE receptors or to CSF, 
ApoE-lipoprotein particles can be modified through a step involving recruitment of 
oligodendrocyte-specific lipids and additional ApoE molecules (Bu, 2009).  
 It has been suggested that AD pathology is heavily influenced by compromised 
cholesterol metabolism within the brain. For example, AD brains tend to have lower 
levels of cholesterol in comparison to healthy brains. With this in mind, it is proposed 
that the different isoforms of ApoE are responsible for compromised cholesterol 
metabolism within the brain (Steinberg, 2009).  
 The different alleles of APOE include ɛ2, ɛ3 and ɛ4, with ɛ3 being the most 
common. The ɛ3 allele is considered to be the normal form of APOE and is present 
within approximately 79% of all ethnic populations (Alzheimer Research Forum, 2010). 
Moreover, the ɛ3 allele is considered a protective agent against late-onset AD (Steinberg, 
2009). The other alleles, ɛ2 and ɛ4 are less common and are found in 7% and 14% of the 
population respectively. The ɛ2 and ɛ4 alleles are known to be the culprit of various 
diseases. For example, individuals homozygous for ApoE ɛ2 are at risk for type III 
hyperlipoproteinemia, whereas those homozygous for ApoE ɛ4 are prone to develop 
atherosclerosis but more importantly late-onset AD (Alzheimer Research Forum, 2010).  
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 The residues at positions 112 and 158 in ApoE account for the structural 
differences among ApoE ɛ2, ApoE ɛ3, and ApoE ɛ4. The most common isoform, ApoE 
ɛ3 has a cysteine at residue 112 and an arginine at residue 158. In contrast, ApoE ɛ2 has 
cysteines at both positions resulting in less binding ability of the protein. Similarly, ApoE 
ɛ4 has arginines at both positions thus affecting the proper function of ApoE 
(Ghebranious, Ivacic, Mallum, & Dokken, 2005). Essentially, because the isoforms 
exhibit different amino acid sequences, the functions of these isoforms will be altered. 
Again, isoforms ɛ2 and ɛ4 are considered abnormal and thus are incapable of carrying out 
the desired activity of the protein (Mahley et al., 2009). With pathology in mind, the main 
residues of concern include the residues associated with the N-terminus (1-191) and the 
C-terminus (225-299), residue 112 and residue 158. The identity of these residues 
ultimately affects the structure and function of the protein. Figure 2 depicts the basic 
structure of ApoE, noting key residues associated with the isoforms of the protein (Hsieh 
& Chou, 2011). 
Role of Apolipoprotein E in APP processing and AD Etiology  
 As mentioned earlier, the ɛ2 and ɛ4 isoforms of ApoE account for a heightened 
predisposition to late-onset AD. Although many factors contribute to the pathology of the 
disease and various hypotheses regarding AD pathology have been proposed, the 
Amyloid Cascade Hypothesis is perhaps the most widely accepted view of AD 
pathology. The foundation of this pathological hypothesis highlights the two main 
pathological hallmarks associated with AD. These hallmarks include intracellular 
neurofibrillary tangles and extracellular amyloid plaques, both of which are found in the 
brain parenchyma (Potter & Wisniewski, 2012).  
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 Vast amounts of research have been devoted to understanding the role of amyloid 
plaques in AD and how these plaques are processed from the amyloid precursor protein 
(APP). Essentially, the mechanism in which APP is processed undoubtedly serves a 
significant role in AD pathology. The production of amyloid plaques in the brain is often 
due to mutations within the APP and PSEN genes. However, new evidence suggests that 
the Amyloid Cascade Hypothesis would not be complete without considering the 
influence of amyloid-associated inflammatory proteins such as α1-antichymotrypsin 
(ACT) and ApoE. Both ACT and ApoE influence amyloid formation by assisting other 
proteins in forming the plaques. In a sense, ACT and ApoE serve as pathological 
chaperones (Potter & Wisniewski, 2012). 
 Before elaborating on how ApoE and other amyloid-associated inflammatory 
proteins play a role in amyloid formation, a basic overview of APP processing should be 
discussed. Two basic pathways exist in APP processing. One path results in the 
production of Aβ peptides while the other path does not produce Aβ peptides (O’Brien & 
Wong, 2011). 
 First, APP is sorted within the endoplasmic reticulum and golgi apparatus. Once 
sorting has been achieved in the golgi apparatus, APP is delivered to the axon, where it is 
transported by fast axonal transport to synaptic terminals. The next few steps in APP 
processing occur at the cell surface and in the trans golgi network (TGN). By way of 
clathrin-associated vesicles, APP is transported from the TGN to either the cell surface or 
directly to an endosomal compartment (O’Brien & Wong, 2011).  
 Mechanisms at the cell surface, although occurring at rapid paces, are extremely 
important in APP processing. Once at the cell surface, APP is proteolyzed by α-secretase 
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and subsequently by γ-secretase. This form of proteolysis does not generate Aβ. 
Proteolysis of APP by α-secretase and γ-secretase is not the only means of processing 
APP once it reaches the cell surface. Clathrin-coated pits can also reinternalize APP into 
an endosomal compartment containing β-secretase and γ-secretase, both of which act as 
proteases. If γ-secretase proteolyzes APP, Aβ is produced. The Aβ peptide is either 
subjected to vesicle recycling and ultimately dumped into the extracellular space, or will 
simply be degraded by the action of lysosomes. Whether APP will be proteolyzed by α-
secretase or will be internalized by endosomes remains unclear. The final step to the APP 
processing cycle entails retromers, which influence communication between endosomal 
compartments and the TGN (O’Brien & Wong, 2011). See Figure 4 for APP processing 
and trafficking.  
 As stated before, ApoE and other amyloid-associated inflammatory proteins 
contribute significantly to AD pathology in the context of amyloid formation and 
inflammation via APP processing, but the main question to be answered is whether the 
plaques and inflammation actually contribute to AD or are merely pathological features 
of AD. In other words, do amyloid plaques and inflammation cause the disease, or does 
the disease promote inflammation and amyloid plaque formation? In an attempt to answer 
this question, research led by Potter and Wisniewski (2012) focused on the influence of 
ACT and ApoE in plaque formation. The main proposition made by Potter and 
Wisniewski was that ACT and/or ApoE stimulate the production of amyloid plaques. 
More specifically, the research done by Potter and Wisniewski revealed that the 
formation of amyloid plaques, stimulated by ACT and/or ApoE, is heavily dependent on 
dose size and isoform type.  
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The ApoE isoform most responsible for promoting plaque formation is ApoE ɛ4. In 
contrast, ApoE ɛ2 acts as an inhibitor in the process of plaque formation (Potter & 
Wisniewski, 2012).  
 One study in particular, led by Manelli and colleagues (2007), helped confirm that 
ApoE and other inflammatory proteins are heavily involved in the amyloid cascade. 
Manelli and colleagues (2007) demonstrated in their research that Aβ neurotoxicity 
significantly increased in the presence of ApoE ɛ4 as compared to ApoE ɛ2 or ɛ3. Based 
off of these findings, Manelli and colleagues confirmed that ApoE ɛ4 constitutes a 
negative gain of function but more importantly plays a significant role in the amyloid 
cascade mechanism. Considering ApoE is an integral component of the amyloid cascade, 
the absence of ApoE would halt the cascade at the harmless point of Aβ monomers. 
Essentially, AD would be nonexistent without the action of ApoE in the amyloid cascade 
(Potter & Wisniewski, 2012). 
 Despite coming across as a completely different function in relation to AD 
pathology, ApoE also acts as an agent in Aβ clearance. Rather than being viewed as a 
destructive agent in the case of contributing to plaque formation, ApoE in the context of 
Aβ clearance serves as a protective agent. When speaking of ApoE in relation to Aβ 
clearance, the ɛ2 and ɛ3 isoforms are more protective than the ɛ4 isoform, which yet 
again confirms that the ɛ4 isoform increases the risk of AD. The protective qualities of 
ApoE were confirmed by further experiments done by Potter and Wisniewski using APP 
transgenic mice carrying a second transgene expressing one or another human ApoE 
isoform. The human ApoE transgene did in fact inhibit the production of amyloid 
deposits confirming the protective qualities of ApoE. However, amyloid did happen to 
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develop in the mice with the ApoE ɛ4 isoform. This isoform ultimately caused plaque 
accumulation to occur earlier and more extensively. From these findings, Potter and 
Wisniewski assumed that human ApoE possibly serves as an inhibitor in the clearance of 
Aβ plaques, with the ɛ4 isoform exhibiting the strongest inhibition (Potter & Wisniewski, 
2012). 
 With a basic understanding of two functions that ApoE serves in the amyloid 
cascade, a more detailed explanation of the actual amyloid cascade mechanism with an 
emphasis placed on the exact role of ApoE in the mechanism is worth mentioning. 
Amyloid precursor protein serves as the starting point in the production of Aβ plaques. 
However, the production of amyloid plaques is not always the final outcome of APP 
processing. The final outcome of APP depends on which proteins are interacting in the 
cascade mechanism. Essentially, as APP goes through the processing cascade as 
described in brief earlier, ApoE eventually participates in the process in its ability to bind 
Aβ (O'Brien & Wong, 2011).  
 ApoE is involved in the secretory pathway of APP processing and enters the 
pathway once the cell has internalized APP by the action of clathrin-mediated proteins. 
Once the cell has internalized APP, APP becomes a part of an early endosome with the 
assistance of ApoE and LRP1. Interestingly, amyloidogenic or non-amyloidogenic 
processing can occur at this point. The type of processing that will ensue depends 
primarily on which ApoE receptors are directly involved in the process. Specifically, 
ApoE receptor 2 allows for APP retention at the cell surface thus promoting non-
amyloidogenic processing. In contrast, in the presence of ApoE ɛ4 and LRP1, 
amyloidogenic processing will ensue ultimately resulting in intraneuronal Aβ 
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accumulation. Moreover, research has shown that if APP is overexpressed in neuronal 
cells, ApoE ɛ4 will increase the production of Aβ. Keeping in mind the combined actions 
of ApoE ɛ4 and LRP1 in APP processing, one can further understand the reasoning 
behind the idea that ApoE ɛ4 stimulates plaque formation (Bu, 2009).  
 After reaching the early endosome stage, further APP processing is carried out by 
β-secretase and γ-secretase. Although either non-amyloidogenic or amyloidogenic 
processing can occur based on which ApoE receptors are involved, the type of proteases 
at work in the process also have a profound effect on the end result of APP processing. 
Both the non-amyloidogenic and amyloidogenic pathways and how α-, β-, and γ-
secretases are involved in these pathways are clearly illustrated in Figure 5 (Wilquet & 
Strooper, 2004). In the non-amyloidogenic pathway, α-secretase first cleaves 
membranous APP producing APPsα. Next, γ-secretase cleaves the α-carboxy terminal 
fragment of APPsα generating a p3 peptide and APP intracellular domain (AICD). In the 
amyloidogenic pathway, β-secretase is used in place of α-secretase thus resulting in the 
production of APPsβ and membrane-anchored β-carboxy terminal fragment. Next, γ-
secretase cleaves the membrane bound β-carboxy terminal fragment thus generating Aβ 
and AICD (Wilquet & Strooper, 2004). The generated Aβ then accumulates 
intraneuronally (Bu, 2009).  
 As mentioned earlier, ApoE acts not only in mediating APP processing but also in 
mediating Aβ clearance. Despite aggregation of Aβ in the brain, there is opportunity for 
Aβ to be cleared. Two pathways of Aβ clearance have been identified, both of which are 
depicted in Figure 6. The first pathway is receptor-mediated clearance and involves the 
combined effects of microglia, astrocytes, and neurons within the interstitial fluid 
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drainage pathway or the blood-brain barrier (BBB). ApoE also contributes significantly 
to this pathway. ApoE can elicit good or bad outcomes to Aβ clearance depending on 
which isoform serves as the mediator in the process. For example, isoforms ɛ2 and ɛ3 
bind Aβ directly and have relatively high binding affinity for Aβ. The resulting ɛ2- and 
ɛ3-Aβ complexes are then transferred to the BBB where they will then be delivered to 
lysosomes to be degraded or to be transcytosed into the plasma for final clearance. In 
contrast, ApoE ɛ4 fails to successfully clear Aβ because it has very poor binding affinity 
for Aβ. Ultimately, clearance mediated by ApoE ɛ4 leads to highly toxic intraneuronal 
Aβ accumulation. The other Aβ clearance pathway is executed by proteolytic 
degradation. Various enzymes produced by neurons or glia act directly in proteolytic 
degradation, but ApoE ɛ4 reduces the expression of these enzymes thus affecting proper 
clearance of Aβ. Recognizing that ApoE has the potential to bind Aβ with high affinity, it 
is clearly demonstrated that Aβ essentially distracts ApoE from performing its duties in 
brain lipid metabolism (Bu, 2009).  
Apolipoprotein E as a Therapeutic Target 
 To date, only five drugs are FDA approved to treat AD. These drugs include 
memantine and acetylcholinesterase inhibitors, tacrine, donepezil, rivastigmine and 
galantamine. These drugs improve overall cognition in people with AD but are not 
capable of slowing the progression of AD. Moreover, these drugs are of no value to those 
in advanced stages of AD (Fenili & McLaurin, 2005). In a sense, the worst damage has 
already been done, and the approved drugs on the market have minimal positive results. 
Developing therapies that target earlier pathological changes is greatly needed.  
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Considering ApoE is directly involved in earlier critical steps in the pathology of AD, 
ApoE stands as a promising therapeutic target.  
 Several different strategies have been proposed in developing effective 
therapeutic models for AD, most of which focus on regulating ApoE expression and 
function. One promising strategy is to change the structure of ApoE ɛ4 to better resemble 
ApoE ɛ3 since ApoE ɛ4 is more often responsible for AD pathology. Molecules such as 
GIND-25, a disulfonate, and GIND-105, a monosulfoalkyl have demonstrated the 
capability of altering the structure of ApoE ɛ4 to mimic the structure of ApoE ɛ3 thus 
limiting the production of Aβ plaques (Bu, 2009).  
 Regulating ApoE expression levels in the brain stands as a potential therapeutic 
strategy as well. It has been suggested that increasing the expression of all ApoE 
isoforms may slow down the progression of AD. In implementing this strategy, 
consideration should be taken in that increasing ApoE ɛ4 expression could result in 
harmful effects, primarily slowing down Aβ clearance. Ultimately, this approach in 
managing expression levels of ApoE should be approached carefully since ApoE ɛ4 can 
affect the brain in two different ways, either by loss of protection or gain of toxicity (Bu, 
2009).  
 An additional therapeutic strategy is to take advantage of liver X receptors, which 
are oxysterol receptors acting as transcription factors. Being transcription factors, liver X 
receptors are responsible for upregulating ApoE in the brain, ultimately promoting 
cholesterol efflux in neurons and glia. Moreover, liver X receptors act as agonists, thus 
aiding in the clearance of Aβ (Bu, 2009).  
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 Considering ApoE is directly involved in Aβ deposition, another promising 
therapeutic model could be disrupting ApoE-Aβ interaction. Disruption is possible by 
implementing a synthetic Aβ peptide that resembles the ApoE-binding site on a full-
length Aβ molecule. This synthetic Aβ peptide has been tested in amyloid mouse models 
and has proved to be quite successful in that it was BBB permeable and non-toxic. 
Additionally, the synthetic Aβ peptide significantly reduced total brain Aβ levels and Aβ 
plaques and sharpened memory performance in two amyloid mouse models (Bu, 2009).  
 Other possible therapeutic targets are ApoE receptors as they are heavily involved 
in brain ApoE-lipoprotein metabolism and Aβ clearance. LRP1 and LDLR, specifically, 
serve as promising targets for therapeutic measures considering decreased levels of LRP1 
are observed in AD brains. It is possible that increasing LRP1 expression may result in 
more effective Aβ clearance thus halting the progression of AD. Furthermore, finding a 
way to block the interaction between APP and ApoE receptors in APP processing has a 
promising outcome (Bu, 2009). 
Epigenetics and Environmental Factors in Alzheimer’s Pathology 
 Understanding the genetic risk factors of AD, such as the role of ApoE 
polymorphisms in AD pathology, is certainly a step forward in developing treatments and 
other clinical interventions for the disease. However, current knowledge of how 
epigenetics and environmental factors influence AD pathology heralds promising 
preventive measures in warding off the disease. More remains to be known about the link 
between genes and environmental factors, but recent evidence indicates that regardless of 
a person’s genetic predisposition, his or her risk for AD can be substantially lowered by 
lifestyle changes.  
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General epigenetic mechanisms in relation to ApoE will be discussed in order to 
understand how lifestyle changes can potentially prevent AD. 
Epigenetic Mechanisms 
 Epigenetics, an emerging field of study, seeks to explain how environmental 
factors have the potential to influence changes in phenotype through alterations in the 
transcriptional activity of various genes (Welsh-Bohmer et al., 2010). Essentially, gene 
expression is not entirely dependent on DNA sequence and can thus be modified by 
certain epigenetic mechanisms. Inhibiting transcriptional access to certain genes is the 
basis of epigenetic mechanisms, and some evidence shows that environmental factors 
such as diet, hazardous exposures, and certain life events are involved in these epigenetic 
mechanisms (Mastroeni et al., 2011). Interestingly, epigenetic modifications can occur in 
two different realms. In one case, specific gene loci in specific cells can be subject to 
modifications while in other cases, multiple genes in a variety of cells can be subject to 
modifications. The latter case is thought to be involved in aging, the greatest risk factor 
for AD (Mastroeni et al., 2011). To understand how environmental factors are translated 
to epigenetic modifications of certain genes, it is best to be aware of the different types of 
epigenetic mechanisms.  
 Epigenetic mechanisms can be subdivided into three primary categories, which 
include histone modifications, DNA methylation, and RNA-related mechanisms. For the 
sake of brevity, only DNA methylation will be covered in detail. First, however, a basic 
overview of histone modification will be discussed, considering DNA methylation is a 
form of histone modification (Mastroeni et al., 2011). 
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 Histones are proteins responsible for packaging and ordering DNA into 
nucleosomes, the structural units of chromosomes. DNA winds around these histone 
proteins like thread on a spool. Although their primary function rests in DNA packaging 
and ordering, histones also play a significant role in gene regulation (Cramer & 
Wolberger, 2011). The principal means by which histones influence gene regulation is 
through conformational changes in protein structure of the histones. Moreover, how DNA 
wraps around the histones can influence gene regulation. The transcriptional machinery 
thus has altered access to the regions that have been modified by the two mechanisms 
previously mentioned. Various mechanisms are known to modify histones. Such 
mechanisms include acetylation, methylation, phosphorylation, ubiquitination, 
sumoylation, citrullination, and adenosine diphosphate ribosylation. Of these mechanisms 
histone acetylation and methylation are the most common forms of histone modification 
and the most well understood mechanisms. Histone acetylation causes conformational 
relaxation of the chromatin by neutralizing the histone proteins. Due to the neutralization, 
the histone protein tails interact more weakly with the negatively charged phosphate 
groups on the DNA. Now in a relaxed state, certain genes are more easily accessible to 
transcriptional machinery and DNA methylation is now possible. In reverse, if the histone 
proteins are deacetylated, the chromatin becomes more condensed, ultimately causing the 
genes in that region of DNA to be inaccessible (Mastroeni et al., 2011). 
 DNA methylation is perhaps the most well understood epigenetic mechanism. 
Interestingly, DNA methylation often acts in part with acetylation, as previously 
mentioned. Due to its heavy influence in histone modification, DNA methylation can be 
thought of as its own class of epigenetic mechanism despite being a form of histone 
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modification (Mastroeni et al., 2011). As the name suggests, DNA methylation modifies 
genome function and chromosomal stability by methylating DNA, specifically the 
cytosine in CpG dinucleotides (Bollati et al., 2011). Any CpG site, whether in coding or 
noncoding regions, has the potential to be methylated. Regions of DNA rich in CpG sites 
are often referred to as CpG islands, and interestingly, the human genome is known to 
have over 50,000 CpG islands. Furthermore, CpG shores, regions within 2 kb of CpG-
enriched sequences have been shown to be methylated, but in a tissue specific manner 
(Mastroeni et al., 2011).  
 The enzymes responsible for carrying out DNA methylation include the DNA 
methyltransferases, DNMT1, DNMT2, DNMT3a/b, and DNMT4. Prior to methylation, 
histone acetylation must occur to allow the DNA to be accessible to methylation. With 
the DNA now accessible, the enzymes are able to incorporate methyl groups into the 
genome. The source of the methyl groups used in this process is methyltetrahydrofolate. 
The methyl group is then transferred from S-adenosylmethionine to the cytosine in the 
CpG site (Mastroeni et al., 2011). Methylation of the CpG regions is associated with gene 
silencing. However, active transcription ensues if the body of the gene is methylated 
(Balazs, Vernon & Hardy, 2011).  
 Although DNA methylation serves various functions, its primary purpose is to 
alter gene expression. DNA methylation can alter gene expression by several different 
mechanisms, but only three mechanisms will be mentioned here. The first mechanism in 
which methylation can alter gene expression is by inducing histone modifications that are 
involved in preventing transcriptional machinery from accessing a gene. Essentially, 
genes that are highly methylated become repressed, and genes that are scarcely 
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methylated undergo enhanced expression or overexpression. Some exceptions to this 
pattern do exist. The second mechanism in which DNA methylation alters gene 
expression is through methyl-CpG-binding proteins (MeCPs). For example, MeCP2 
binds to methylated DNA triggering histone deacetylases to cause the chromatin to 
become more condensed ultimately preventing access to certain genes. In some cases, 
MeCP2 does not depend on DNA methylation or histone deacetylation to condense 
chromatin. The final epigenetic mechanism involved in DNA methylation is 
hydroxymethylation, which occurs when 5-methylcytosines are oxidized to 5-
hydroxymethylcytosines. The transformation of 5-methylcytosine to 5-
hydroxymethylcytosine ultimately causes certain genes to be highly restricted. Neurons 
have shown to exhibit hydroxymethlation, which is thought to be a result of oxidative 
damage and/or oxidative enzymes (Coppieters & Dragunow, 2011). See Figure 7 for a 
brief overview of DNA methylation 
Epigenetic Mechanisms in Alzheimer’s Pathology 
 As research continues to reveal the specifics of how histone modifications and 
DNA methylation function in altering gene function and transcription, more can begin to 
be explained in regard to the relationship between environmental factors and AD 
pathology. Although not officially confirmed in literature, environmental factors are very 
likely to be the cause of epigenetic modifications resulting in diseases ranging from 
cancer to AD. Regarding DNA methylation, several studies have shown that the genomes 
of people with AD tend to be hypomethylated. However, in some cases it has been 
observed that certain genes, primarily nucleolar rRNA genes, are hypermethylated. 
Hypermethylation of rRNA genes is thought to be a major contributor to AD pathology 
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due to ribosomal deficiencies that result from the hypermethylation. In short, people with 
AD tend to have altered DNA methylation patterns in comparison with healthy 
individuals (Leszek, Sochocka & Gąsiorowski, 2012). As more is understood regarding 
these DNA methylation patterns in normal aging brains versus AD brains, the 
relationship between DNA modifications and AD pathology can be better explained 
(Coppieters & Dragunow, 2011).  
 Equally important is the fact that DNA hypomethylation is known to be 
associated with aging, the greatest risk factor for developing AD. The correlation 
between aging and AD and how DNA methylation is involved in AD pathology opens up 
many new prospects in understanding both the aging process and AD pathology. To 
investigate this correlation, Ladd-Acosta et al., (2007) conducted a study using bisulfite 
conversion. The main conclusion drawn from this study was that DNA methylation levels 
at specific CpGi loci increased with increasing age (Ladd-Acosta et al., 2007).  
 Although DNA methylation is directly involved in tau and neurofibrillary tangle 
formations and in Aβ-related mechanisms, it does have possible association with ApoE as 
well. Not much research has focused on the methylation status of APOE thus far 
(Mastroeni et al., 2011). However, some evidence has suggested that the APOE promoter 
is poorly methylated. Interestingly, the degree of methylation does vary among the 
different APOE alleles. For example, the methylation of CpG sequences are evident in 
the ε4 allele but not in the ε2 or ε3 alleles (Wang, Oelze & Schumacher, 2008). In review, 
the ε4 allele stands as a significant risk for developing AD.  
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Interestingly, however, having the ε4 allele does not ensure the development of AD, 
which begs the question of whether or not methylation status at ε4 CpG sites is altered in 
ε4 carriers who end up developing AD (Mastroeni et al., 2011).  
Inducing Epigenetic Changes via Environmental Factors 
 Much more can be said about epigenetic mechanisms, but of particular interest is 
identifying certain environmental factors that may induce epigenetic mechanisms. As 
mentioned before, aging is the greatest risk factor for AD and thus stands as a primary 
inducing factor in epigenetic mechanisms. Aging clearly cannot be evaded and therefore 
serves as a poor modifiable agent (Welsh-Bohmer et al., 2010). Other environmental 
factors, however, are promising modifiable agents. Many different environmental factors 
have been studied, including lead, arsenic, tobacco, education, diet, and engagement in 
physical activity to name a few. 
 Although all of the aforementioned factors are important in epigenetic 
mechanisms, the discussion here will focus on diet. A study conducted by Gu et al. 
(2010) demonstrated the effects of diet on AD development. The dietary patterns of 2000 
subjects were analyzed. Only 253 people developed AD, but Gu et al. confirmed that 
diets rich in omega-3 and omega-6 polyunsaturated fatty acids, vitamin E, and folate, 
along with limited consumption of saturated fatty acids and vitamin B12, reduced the risk 
of AD. Moreover, those who ate more fruits and vegetables and less animal products 
lowered their chances of developing AD. The reason that eating less meat protects against 
AD is that meat contains high levels of vitamin B12, a risk factor for AD. Likewise, 
eating more fruits and vegetables protects against AD because of the high levels of 
vitamin C found in these foods.  
APOE AND ENVIRONMENT  26 
Interestingly, vitamin C has been found to decrease DNA methylation, specifically in 
human embryonic stem cell lines, HES2 and HES3 (Coppieters & Dragunow, 2011).  
 Similar to the findings of Gu et al., Dr. Campbell (2006), author of The China 
Study, has found after a twenty-seven-year laboratory program funded by the National 
Institutes of Health, the American Cancer Society and the American Institute for Cancer 
Research, and after four decades of biomedical research that a healthy diet, primarily a 
plant-based diet, has the potential to prevent diseases such as AD. Such a diet has the 
potential to prevent not only AD but also other diseases such as heart disease and 
diabetes, both of which are risk factors for AD. Campbell provides several arguments that 
are consistent with one another and support the notion that diet has a profound effect on 
AD development. One argument rests on recent studies focusing on the prevalence of AD 
in Japanese men living in Hawaii versus Japanese men living in Japan. According to this 
study, The Japanese American men had much higher rates of AD than the Japanese men 
living in Japan. Similarly, an additional study found that African American men living in 
Indiana had significantly higher rates of dementia and AD than native Africans. A more 
broad study, focusing on dietary habits in eleven different countries, found that 
populations with high fat intake and low cereal and grain intake experienced higher rates 
of AD. As illustrated by the previously mentioned studies, dietary habits have a profound 
effect on AD pathology (Campbell & Campbell, 2006). In addition, one can gather from 
these findings that the typical American diet, which is commonly high in saturated fat 
and animal protein acts as a significant culprit in the development of AD.  
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Concluding Remarks 
 Since its initial discovery by Alois Alzheimer about 100 years ago, AD has left in 
its path a history of harrowing endings for many individuals and families. However, 
throughout the same historical timeline, much scientific advancement has been made both 
in the realm of therapeutic and preventive approaches, thus giving hope for a brighter 
future. AD is a complicated disease involving a myriad of risk factors, ranging from 
genetic factors to environmental factors. Of recent interest is the role ApoE plays in AD 
pathology and how lipid metabolism within the brain can be drastically impaired due to 
minor structural differences in ApoE. Further investigation of the direct impact that 
various ApoE isoforms have on lipid and cholesterol metabolism will help elucidate the 
questions yet to be answered regarding AD.  
 The relationship between epigenetic mechanisms and environmental factors is 
equally important in the study of AD pathology, and research in this realm has gained 
much more momentum in recent years. Despite the wealth of knowledge acquired in such 
a short amount of time in the discipline of epigenetics, much still remains to be known 
about the mechanisms involved. More is known how epigenetic mechanisms associate 
with APP, but very little is known about ApoE and epigenetic mechanisms. For example, 
future research could focus on the methylation status of ApoE isoforms and how this 
affects AD pathology. Likewise, delineating how environmental factors such as diet have 
a direct influence on the control of epigenetic mechanisms is greatly needed to advance 
our knowledge about AD. Much encouragement can be taken from the fact that 
environmental factors like diet play a significant role in AD pathology. Making simple 
lifestyle changes may possibly be the key to warding off AD.  
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Appendix 
 
Table 1. Commonly used abbreviations. 
ABCA-1 ATP-binding cassette, sub-family A 
ACT α1-antichymotrypsin 
AD Alzheimer’s disease 
APOE Apolipoprotein E 
APP Amyloid precursor protein 
BBB Blood brain barrier 
DNA Deoxyribonucleic acid 
LDL Low-density lipoprotein 
LDLR Low-density lipoprotein receptor 
LRP1 
Low-density lipoprotein receptor-related 
protein 1 
TGN Trans golgi network 
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Figure 1. Projected Numbers of People Age 65 and Over in the U.S. Population with 
Alzheimer’s Disease Using the U.S. Census Bureau Estimates of Population 
Growth* 
 
*Numbers indicate middle estimates per decade. Colored area indicates low and high 
estimates per decade.  
 
(Alzheimer's Association, 2012, p. 19). 
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Figure 2. The N-and-C-terminal domains of human ApoE are important in both the 
structure and function of ApoE. The N-terminal domain of ApoE contains the LDL 
receptor binding region while the C-terminal domain contains the lipid binding region. 
Residues 112 and 158 of the E2, E3, and E4 isoforms are also important as amino acid 
differences among these isoforms account for altered structure and function of ApoE 
(Hsieh & Chou, 2011, p. 2). 
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Figure 3. The action of ApoE is crucial to proper neuronal function. First, astrocytes 
secrete ApoE, which assembles lipids and cholesterol into lipoprotein particles. ABCA1 
is a plasma membrane transporter responsible for loading the lipids onto ApoE. The 
newly assembled ApoE-lipoprotein particle (as depicted in the inset) can undergo 
modifications before binding to receptors on neurons. Once ApoE binds to receptors on 
neurons, synapse formation and repair can occur (Bu, 2009, p.8). 
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Figure 4. APP trafficking in neurons is a process necessitating various components. 
“Newly synthesized APP (purple) is transported from the Golgi down the axon (1) or into 
a cell body endosomal compartment (2). After insertion into the cell surface, some APP is 
cleaved by α-secretase (6) generating the sAPP α fragment, which diffuses away (green), 
and some is reinternalized into endosomes (3), where Aβ is generated (blue). Following 
proteolysis, the endosome recycles to the cell surface (4), releasing Aβ (blue) and sAPP 
β. Transport from the endosomes to the Golgi prior to APP cleavage can also occur, 
mediated by retromers (5)” (O'Brien & Wong, 2011, p. 191). 
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Figure 5. APP can be processed by way of two pathways. Both amyloidogenic and 
non-amyloidogenic pathways are possible in APP processing. β- and γ-secretase are 
involved in the amyloidogenic pathway whereas α- and γ-secretase are involved in the 
non-amyloidogenic pathway (Wilquet & Strooper, 2004). 
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Figure 6. ApoE is also involved in Aβ clearance. The two major pathways in which 
ApoE clears Aβ deposits are receptor-mediated clearance and clearance by proteolytic 
degradation by endopeptidases. The different effects of ApoE E3 and E4 are noted. 
LDLR-related protein 1 (LRP1) is heavily involved in the receptor-mediated clearance 
pathway by binding to Aβ directly (Bu, 2009, p.7). 
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Figure 7. DNA methylation is an important means for altering gene expression. 
Chromatin, which is made of histones (blue cylinders) and DNA, is transcriptionally 
active in a relaxed state. Chromatin transitions to the relaxed state when acetyl groups 
(green blocks) are transferred from acetyl-coenzyme A to histone tails (red rods) by way 
of histone acetyltransferases (HATs). DNA methylation occurs at the cytosines of 
adjacent C-G/G-C dinucleotides by the action of DNA methyltransferases (DNMTs). 
Methyl groups originate from methyltetrahydrofolate in conjunction with the 
methionine/homocysteine cycle. CpG-methyl-binding-domain proteins (MBDs) and 
methylation complex proteins (MeCps), which attract histone deacetylases (HDACs), are 
involved in further inhibition of transcriptional access (Mastroeni et al., 2011, p. 1163).
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